Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
David Sarid
38 years of experience
accreditations :
Clinic is certified :
Lutetium-177 therapy in Israel typically costs from $16,500 to $22,800 per treatment cycle. Total expenses depend on the specific cancer type, diagnostic imaging requirements, and the hospital location in Tel Aviv or Jerusalem. Patients in the US pay around $45,000 on average. Choosing Israel offers savings of approximately 56%. Costs generally cover the radiopharmaceutical drug, administration, and short-term hospitalization.
Bookimed Expert Insight: Israel provides world-class oncology care with unique access to pioneers like Dr. Inna Ospovat at Sourasky Medical Center (Ichilov). While Hadassah Medical Center offers PRRT for approximately $30,000 including PET-CT, Ichilov starts around $16,500 per cycle. This price gap often reflects different diagnostic inclusions rather than quality. Patients benefit from 90% oncology success rates at JCI-accredited facilities without the US price tag.
Why choose Israel for lutetium-177 therapy?
Access advanced Lutetium-177 therapy solutions in trusted clinics .
| Israel | Turkey | Austria | |
| Lutetium-177 therapy | from $16,500 | from $8,800 | from $35,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Lutetium-177 therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Lutetium-177 therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Lutetium-177 therapy journey.
Day 1
Day 2
Day 3
Day 4
Day 5
Week 1-2 Post Therapy
Week 3-4 Post Therapy
Week 5-6 Post Therapy
Please note that each patient"s case is unique and the timeline may vary.
What patients like:
What patients don't like:
As the leading global medical tourism platform, Bookimed.com takes huge responsibility to provide the most objective and transparent information to our clients, both patients, and medical centers, looking for Lutetium-177 therapy services in Israel. All the information provided on Bookimed.com is grounded in research, foresight, and expertise and meets high interest related to the product and follows:
We form our listings of clinics and doctors with strict regulations of our smart automatic ranking system. The system is based on real Bookimed patient rates to provide the most objective and transparent information about clinics and Lutetium-177 therapy medical services in Israel.
Our experienced data scientist collects data daily, monitors and optimizes the ranking system using machine learning and artificial intelligence to ensure that the ranking system is up-to-date and provides accurate results.
We collect the opinions of Bookimed clients only after getting medical experience with the clinic — so everyone on the platform can trust the facility they choose for Lutetium-177 therapy in Israel. We strive to make the content on our platform as useful as possible and ensure the freedom to express critical opinions. Thus, we publish positive and negative reviews, aiming at being a source for informed decision-making for our future clients.
On Bookimed.com, you may find choice and convenience to find the best medical solutions from top medical services providers of Lutetium-177 therapy in Israel just in one place, and often at competitive prices. Making sure to deliver the freshest information, the clinic’s representatives update doctors’ CVs, clinics’ capacities, before-after pictures, prices, packages, and specials by themselves shortly. You may meet the clinic’s representative and check the date of updated content at every clinic’s page to make sure of its trustworthiness.
Our blog and supportive pieces are created by professional authors with at least 3-year experience in medical writing and edited by medical specialists with relevant clinical and research expertise — all carefully recruited to the team. We strive to enhance patient access to health information, making it expert but easy to understand. All pieces follow the Bookimed’s Editorial Guidelines.
We are made of people and for people — and that"s our core value. That"s why all the data presented on the platform is collected, edited, reviewed, and updated regularly by our patients, our partner clinics, and our team, including the Bookimed Medical Advisory Board, which consists of the world-renowned doctors with value expertise over 20 years of practice, and a positive reputation. Learn more about us and our mission.
In case you find any mistake or have any questions on the information presented on Bookimed.com regarding Lutetium-177 therapy services in Israel, please feel free to contact us at marketing@bookimed.com.
Leading expert in Lutetium-177 therapy – Dr. Raphael integrates cutting-edge genomic profiling with targeted radionuclide treatments at Sourasky Medical Center.
Prof. Merimsky leads the Unit for Orthopedic Oncology at Sourasky Medical Center, specializing in advanced therapies like Lutetium-177.
2,200 rhinoplasties over 17 years – Dr. Yılmaz works exclusively on noses at Memorial Hospital in Istanbul.
Director of oncology hospitalization at Sourasky Medical Center – Dr. Stepfansky specializes in advanced treatment protocols.
Written by Kateryna Zamkovska
Lutetium-177 therapy is a targeted radiotherapy utilizing the Lutetium-177 radioisotope to treat certain cancers effectively.
Lutetium-177 therapy in Israel is a targeted nuclear medicine treatment for metastatic prostate cancer and neuroendocrine tumors. Using PSMA or DOTATATE ligands, it delivers precise beta radiation to malignant cells. Leading JCI-accredited centers like Sourasky and Hadassah offer this molecular therapy to international patients.
Bookimed Expert Insight: Israeli oncology centers like Sourasky provide a unique advantage by integrating Foundation One CDx genetic testing with Lutetium-177 protocols. This ensures your specific tumor biology matches the radioligand before you commit to the full $16,500 treatment cycle. It helps avoid ineffective therapy sessions.
Patient Consensus: Patients emphasize the necessity of confirming receptor expression via PET scan first. Many suggest using ice chips during the infusion to successfully manage dry mouth symptoms.
Lutetium-177 therapy is generally well-tolerated, though it carries risks like bone marrow suppression, kidney toxicity, and xerostomia. Patients often experience temporary fatigue and nausea during the first week. In Israel, specialists at JCI-accredited centers use precise dosing to manage these radiation-related side effects effectively.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center maintain a high 90% success rate by integrating medical physicists into the care team. Experts like Dr. Inna Ospovat use advanced protocols to shield healthy organs. This multidisciplinary approach ensures radiation hits the tumor while minimizing long-term damage to the kidneys and salivary glands.
Patient Consensus: Many patients find managing dry mouth with sour candies helpful. Most emphasize the need for total rest during the first week due to sudden, intense fatigue.
Lutetium-177 therapy effectively extends lives by delivering targeted radiation to cancer cells. Patients often see median survival rates increase to 15.3 months, compared to 11.3 months with standard care. This molecular therapy significantly reduces PSA levels in 30% to 70% of advanced cases.
Bookimed Expert Insight: Israeli centers like Sourasky Medical Center provide targeted Lutetium-177 therapy for $16,500 to $22,800. This is roughly 56% less than the $45,000 US average. Expert Nuclear Therapy Specialist Dr. Inna Ospovat emphasizes that completing 5 or more cycles significantly improves survival outcomes compared to shorter courses.
Patient Consensus: While not a cure, patients frequently report better quality of life and reduced bone pain. Many note that managing dry mouth early is vital as this side effect can become permanent without proactive monitoring.
Lu-177 therapy involves intravenous infusion of radioactive isotopes to target prostate or neuroendocrine tumors. Preparation requires PET/CT imaging to confirm receptor expression and blood tests for kidney function. The procedure lasts 4 hours as a daycare visit, with patients following radiation safety protocols for 3 days post-treatment.
Bookimed Expert Insight: Israeli centers like Sourasky Medical Center provide Lu-177 through a multi-disciplinary team led by specialists like Inna Ospovat. While the radioactive injection is brief, the full appointment is a 4-hour process due to mandatory pre-hydration and amino acid infusions. Proactive use of sugar-free gum helps manage xerostomia, a common cumulative side effect observed in patients undergoing multiple cycles.
Patient Consensus: Patients emphasize the importance of sitting while urinating and sleeping separately for 3 days to protect family. Most report manageable fatigue and advise bringing comfort items for the long daycare infusion sessions.
Lutetium-177 therapy is available at JCI-accredited facilities in Israel like Sourasky Medical Center and Hadassah Medical Center. Specialized nuclear medicine departments utilize Peptide Receptor Radionuclide Therapy (PRRT) and PSMA ligands to treat metastatic prostate cancer and neuroendocrine tumors through high-precision intravenous administration.
Bookimed Expert Insight: Sourasky Medical Center treats 40,000 cancer patients annually using tools like the Novalis TrueBeam accelerator. While treatment costs $16,500 to $22,800 here, it remains highly competitive. You save approximately 56% compared to US prices of $45,000.
Patient Consensus: Patients emphasize that this targeted radioligand treatment is a vital option for metastatic cases. Many advise confirming eligibility with oncology centers regarding previous failures in hormone or chemotherapy.